GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Shiller PE Ratio

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Shiller PE Ratio : 2.94 (As of May. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Shiller PE Ratio?

As of today (2024-05-14), Eagle Pharmaceuticals's current share price is $4.67. Eagle Pharmaceuticals's E10 for the quarter that ended in Jun. 2023 was $1.59. Eagle Pharmaceuticals's Shiller PE Ratio for today is 2.94.

The historical rank and industry rank for Eagle Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

EGRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 2.62   Med: 12.09   Max: 29.15
Current: 2.94

During the past years, Eagle Pharmaceuticals's highest Shiller PE Ratio was 29.15. The lowest was 2.62. And the median was 12.09.

EGRX's Shiller PE Ratio is ranked better than
97.74% of 532 companies
in the Drug Manufacturers industry
Industry Median: 25.285 vs EGRX: 2.94

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Eagle Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2023 was $0.390. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.59 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eagle Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Eagle Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Shiller PE Ratio Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 21.00

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 20.49 21.00 18.56 12.24

Competitive Comparison of Eagle Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eagle Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Shiller PE Ratio falls into.



Eagle Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Eagle Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=4.67/1.59
=2.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Eagle Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.39/128.7287*128.7287
=0.390

Current CPI (Jun. 2023) = 128.7287.

Eagle Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -0.061 98.790 -0.079
201312 -0.315 98.326 -0.412
201403 -0.360 99.695 -0.465
201406 -0.210 100.560 -0.269
201409 -0.650 100.428 -0.833
201412 -0.390 99.070 -0.507
201503 1.310 99.621 1.693
201506 -0.530 100.684 -0.678
201509 -0.650 100.392 -0.833
201512 0.070 99.792 0.090
201603 -0.060 100.470 -0.077
201606 0.800 101.688 1.013
201609 0.730 101.861 0.923
201612 3.520 101.863 4.448
201703 1.420 102.862 1.777
201706 0.280 103.349 0.349
201709 0.980 104.136 1.211
201712 0.580 104.011 0.718
201803 0.170 105.290 0.208
201806 0.170 106.317 0.206
201809 0.910 106.507 1.100
201812 0.860 105.998 1.044
201903 0.620 107.251 0.744
201906 0.480 108.070 0.572
201909 -0.170 108.329 -0.202
201912 0.070 108.420 0.083
202003 -0.210 108.902 -0.248
202006 -0.020 108.767 -0.024
202009 0.510 109.815 0.598
202012 0.590 109.897 0.691
202103 -0.030 111.754 -0.035
202106 0.270 114.631 0.303
202109 -0.430 115.734 -0.478
202112 -0.480 117.630 -0.525
202203 3.410 121.301 3.619
202206 -0.740 125.017 -0.762
202209 -0.540 125.227 -0.555
202212 0.620 125.222 0.637
202303 0.440 127.348 0.445
202306 0.390 128.729 0.390

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eagle Pharmaceuticals  (NAS:EGRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Eagle Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Executives
Scott Tarriff director, officer: President and CEO 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran officer: EVP, Chief Commercial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill officer: Chief Financial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin officer: Chief Medical Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp director C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc director 1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein director HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum director 630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers officer: Chief Financial Officer C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock director 405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p. 10 percent owner 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill officer: Chief Scientific Officer C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Headlines

From GuruFocus